1. Academic Validation
  2. Levetiracetam: a novel antiepileptic drug

Levetiracetam: a novel antiepileptic drug

  • Pharmacotherapy. 2001 Nov;21(11):1375-88. doi: 10.1592/phco.21.17.1375.34432.
C A Hovinga 1
Affiliations

Affiliation

  • 1 Department of Pharmacy and Neurology, Cleveland Clinic Foundation, Ohio 44195, USA. hovingc@ccf.org
Abstract

Levetiracetam is a new antiepileptic drug, structurally and mechanistically dissimilar to Other marketed antiepileptic drugs. It is effective in reducing partial seizures in patients with epilepsy, both as adjunctive treatment and as monotherapy. Levetiracetam has many therapeutic advantages for patients with epilepsy. It has favorable pharmacokinetic characteristics (good bioavailability, linear pharmacokinetics, insignificant protein binding, lack of hepatic metabolism, and rapid achievement of steady-state concentrations) and a low potential for drug interactions. Recommended starting dosages are considered to be clinically effective; therefore, patients can have some protection from seizures soon after they begin levetiracetam. The most common adverse effects observed with levetiracetam are mild and include somnolence, asthenia, and dizziness. Clinical experience and data from meta-analyses indicate that levetiracetam is well tolerated, with efficacy comparable or slightly better than that observed with Other new antiepileptic drugs. Levetiracetam may be particularly useful in patients who are unresponsive to Other antiepileptic drugs, patients receiving drugs with increased potential for drug interactions, or those with hepatic impairment.

Figures
Products
我们的 Cookie 政策

我们使用 Cookies 和类似技术以提高网站的性能和提升您的浏览体验,部分功能也使用 Cookies 帮助我们更好地理解您的需求,为您提供相关的服务。 如果您有任何关于我们如何处理您个人信息的疑问,请阅读我们的《隐私声明》